TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7424927

Group type: EXPERIMENTAL
Intervention: 0.1 mg epinephrine hydrochloride
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.3 mg epinephrine hydrochloride
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.5 mg epinephrine hydrochloride
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (0.1 mg and 0.3 mg)
Number of subjects: 45
Study: 31699052

Group type: EXPERIMENTAL
Intervention: General anesthesia combined with TAP block (40 mL of 0.375% ropivacaine)
Number of subjects: 65

Group type: COMPARATOR
Intervention: General anesthesia (control group)
Number of subjects: 65
Study: 30113724

Group type: EXPERIMENTAL
Intervention: BI 655064 (80 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: BI 655064 (120 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: BI 655064 (180 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: BI 655064 (240 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 27352504

Group type: EXPERIMENTAL
Intervention: Moxa salt packets at Zhongwan (CV 12) combined with tropisetron hydrochloride (5 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tropisetron hydrochloride (5 mg)
Number of subjects: 60
Study: 24986113

Group type: EXPERIMENTAL
Intervention: QLQ-C30
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: PROMIS
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: SCNS-SF34
Number of subjects: 224
Study: 23237204

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy in addition to orthoses therapy and home orientations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Orthoses therapy and home orientations
Number of subjects: 0
Study: 20302573

Group type: EXPERIMENTAL
Intervention: UVB-LED therapy (high-dose group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: UVB-LED therapy (low-dose group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Untreated control (lesion not treated with UVB-LED)
Number of subjects: 20
Study: 18263937

Group type: EXPERIMENTAL
Intervention: Obese group (BMI >= 85 percentile)
Number of subjects: 1906

Group type: COMPARATOR
Intervention: Non-obese group (BMI between 15 and 75 percentile)
Number of subjects: 1906
Study: 15345158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg after induction and placebo at 12 h postoperatively
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg after induction and 1.25 mg at 12 h postoperatively
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg plus Metoclopramide 10 mg after induction and droperidol 1.25 mg at 12 h postoperatively
Number of subjects: 140
Study: 11594643

Group type: EXPERIMENTAL
Intervention: Aerobic exercise programme (cycling for up to 30 minutes three times weekly for 24-36 sessions over 12 weeks)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Aerobic exercise programme
Number of subjects: 90
Study: 9855387

Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 153

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 153
Study: 8084354

Group type: EXPERIMENTAL
Intervention: Balloon valvuloplasty
Number of subjects: 60

Group type: COMPARATOR
Intervention: Open surgical commissurotomy
Number of subjects: 60
Study: 2819572

Group type: EXPERIMENTAL
Intervention: One-day diet control and oral dulcolax
Number of subjects: 74

Group type: COMPARATOR
Intervention: Three-day diet control and enema
Number of subjects: 74
Study: 811350

Group type: EXPERIMENTAL
Intervention: Abdominal radiation therapy alone
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Chlorambucil alone
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Combination of radiation therapy and chlorambucil
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 51
Study: 31532768

Group type: EXPERIMENTAL
Intervention: cathodal tDCS
Number of subjects: 41

Group type: COMPARATOR
Intervention: sham tDCS
Number of subjects: 41
Study: 28404609

Group type: EXPERIMENTAL
Intervention: Active moxibustion plus placebo gel
Number of subjects: 144

Group type: COMPARATOR
Intervention: Diclofenac sodium gel plus placebo moxibustion
Number of subjects: 144
Study: 25925431

Group type: EXPERIMENTAL
Intervention: BiClamp® forcep transection
Number of subjects: 96

Group type: COMPARATOR
Intervention: Clamp crushing technique
Number of subjects: 96
Study: 23703599

Group type: EXPERIMENTAL
Intervention: Capsicum plaster at K-D2 with prophylactic antiemetic
Number of subjects: 68

Group type: COMPARATOR
Intervention: Intravenous prophylactic ramosetron 0.3mg (Control)
Number of subjects: 68
Study: 22059309

Group type: EXPERIMENTAL
Intervention: Group intervention aimed at enhancing maternal responsivity, sensitivity, and childrearing behaviour over a period of 14 months starting from the third quarter of pregnancy.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 24
Study: 19407454

Group type: EXPERIMENTAL
Intervention: Pardoprunox (0.3‐42 mg/day)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Pardoprunox (up to 18 mg/day) with intermediate steps
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Pardoprunox (combined group)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 17035558

Group type: EXPERIMENTAL
Intervention: Clubhouse model
Number of subjects: 170

Group type: COMPARATOR
Intervention: PACT model
Number of subjects: 170
Study: 14625336

Group type: EXPERIMENTAL
Intervention: 8 days of antibiotic therapy
Number of subjects: 401

Group type: COMPARATOR
Intervention: 15 days of antibiotic therapy
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: 8 days of antibiotic therapy (in patients with nonfermenting gram-negative bacilli)
Number of subjects: 401

Group type: COMPARATOR
Intervention: 15 days of antibiotic therapy (in patients with nonfermenting gram-negative bacilli)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: 8 days of antibiotic therapy (among patients with recurrent infections)
Number of subjects: 401

Group type: COMPARATOR
Intervention: 15 days of antibiotic therapy (among patients with recurrent infections)
Number of subjects: 401
Study: 16758733

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) level measurement using imunoluminometric assay (LUMItest) and immunochromatographic assay (PCT‐Q)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) level measurement on the first, second, and third day of hospitalization
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) level measurement in sepsis caused by Gram positive and Gram negative bacteria
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) as a diagnostic marker
Number of subjects: 126
Study: 10556117

Group type: EXPERIMENTAL
Intervention: Treadmill six-minute walk test (TM SMWT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Hallway six-minute walk test (HW SMWT)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Comparison of HW SMWT and TM SMWT
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Oxygen saturation and supplemental oxygen requirements
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Intra-test variability of HW and TM SMWT
Number of subjects: 21
Study: 8561059

Group type: COMPARATOR
Intervention: Fish oil supplement (15g) + 0 mg alpha-tocopheryl acetate (placebo)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Fish oil supplement (15g) + 100 mg alpha-tocopheryl acetate
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Fish oil supplement (15g) + 200 mg alpha-tocopheryl acetate
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Fish oil supplement (15g) + 400 mg alpha-tocopheryl acetate
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Fish oil supplement (15g)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Fish oil supplement (15g) + alpha-tocopheryl acetate
Number of subjects: 48
Study: 1927294

Group type: EXPERIMENTAL
Intervention: Nylidrin (13 women)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Indomethacin (12 women)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Pregnant women without uterine contractions
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Women with preterm labor
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Women who went into labor before the 37th gestational week
Number of subjects: 100
Study: 7035687

Group type: EXPERIMENTAL
Intervention: Prophylactic penicillin (5-day course)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 29680222

Group type: EXPERIMENTAL
Intervention: Vocal therapy associated with electromyographic biofeedback
Number of subjects: 22

Group type: COMPARATOR
Intervention: Traditional vocal therapy (Placebo Group)
Number of subjects: 22
Study: 28241822

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 2482

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 2482

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2482
Study: 26158679

Group type: EXPERIMENTAL
Intervention: STEPs-HE intervention
Number of subjects: 1700

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1700
Study: 25003264

Group type: EXPERIMENTAL
Intervention: 12.5% maltodextrin (carbohydrate group)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 12.5% maltodextrin plus 15 g of glutamine (glutamine group)
Number of subjects: 11
Study: 22984450

Group type: EXPERIMENTAL
Intervention: Probiotic supplements
Number of subjects: 16991
Study: 19318465

Group type: EXPERIMENTAL
Intervention: Adaptive Physical Activity (APA-stroke)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 49
Study: 17319855

Group type: EXPERIMENTAL
Intervention: Decision aid
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard consultations
Number of subjects: 30
Study: 15031131

Group type: EXPERIMENTAL
Intervention: Plasma cholesterol (total and HDL)
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Mean arterial blood pressure, gender, age, height, and heart rate
Number of subjects: 868
Study: 11443472

Group type: EXPERIMENTAL
Intervention: Preincisional ketamine 1 mg/kg IV and local infiltration with 20 ml ropivacaine (10 mg/ml)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Preincisional saline IV and local infiltration with 20 ml ropivacaine (10 mg/ml)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo preincisional
Number of subjects: 55
Study: 9709151

Group type: EXPERIMENTAL
Intervention: Lignocaine 1%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 40
Study: 8032178

Group type: EXPERIMENTAL
Intervention: Nasolacrimal occlusion with 2% pilocarpine, 1.5% carbachol, 0.25% timolol maleate, or 1% epinephrine every 12 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nasolacrimal occlusion with 0.25% timolol and 1.5% carbachol every 12 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nasolacrimal occlusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.05% dipivefrin every 12 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Commercially used antiglaucoma agents with nasolacrimal occlusion
Number of subjects: 0
Study: 31784300

Group type: EXPERIMENTAL
Intervention: Teduglutide treatment for 24 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31515704

Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study: 27502413

Group type: EXPERIMENTAL
Intervention: HF-rTMS (N=11)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham stimulation (N=10)
Number of subjects: 21
Study: 26602299

Group type: EXPERIMENTAL
Intervention: Cluster-specific water access and sanitation coverage assessment
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Random sample of households for sanitation coverage
Number of subjects: 13
Study: 23764345

Group type: EXPERIMENTAL
Intervention: Group 1 (fitness sessions and education in healthful eating and physical activity)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Group 2 (fitness sessions only)
Number of subjects: 91
Study: 21531060

Group type: EXPERIMENTAL
Intervention: Bono de Desarrollo Humano (BDH) cash transfer program
Number of subjects: 1196

Group type: COMPARATOR
Intervention: Comparison group (no BDH)
Number of subjects: 1196
Study: 18833170

Group type: EXPERIMENTAL
Intervention: Movalis injected into trigger points (3 injections + 15 mg tablets per day)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Movalis intramuscular injection (3 injections + 15 mg tablets per day)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 94
Study: 16848149

Group type: EXPERIMENTAL
Intervention: General anesthesia with propofol, fentanyl, and vecuronium (G1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Volatile anesthesia with sevoflurane (G2)
Number of subjects: 50
Study: 12635909

Group type: EXPERIMENTAL
Intervention: Message recipients who received a message favoring comprehensive exams
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Message recipients who received a message opposing comprehensive exams
Number of subjects: 3

Group type: COMPARATOR
Intervention: Message recipients in conditions that elicited large amounts of thought
Number of subjects: 3

Group type: COMPARATOR
Intervention: Message recipients in conditions that elicited small amounts of thought
Number of subjects: 3
Study: 11049005

Group type: EXPERIMENTAL
Intervention: Intravenous diclofenac (25 mg)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Intravenous diclofenac (50 mg)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Intravenous diclofenac (75 mg)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Intravenous diclofenac (all doses)
Number of subjects: 269
Study: 9093544

Group type: EXPERIMENTAL
Intervention: High energy breakfast (over 20% of recommended daily energy intake)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Low energy breakfast (less than 10% of recommended daily energy intake)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: High energy breakfast
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Energy intake at breakfast (based on returned food)
Number of subjects: 195
Study: 8509241

Group type: EXPERIMENTAL
Intervention: E85 (85% of IAT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: E95 (95% of IAT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: E100 (100% of IAT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: E105 (105% of IAT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AT100 (100% of AT)
Number of subjects: 30
Study: 2943752

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (CPA) 50 mg/day orally for 3 months
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Depot preparation of LHRH superagonist (DTrp6‐LHRH) 3 mg intramuscularly approximately once a month for 3 months
Number of subjects: 10
Study: 29608680

Group type: EXPERIMENTAL
Intervention: Extended infusion of β-lactams (4 hours)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Bolus infusion of β-lactams (30 minutes)
Number of subjects: 105
Study: 27394386

Group type: EXPERIMENTAL
Intervention: Weight management counseling by telephone before and during pregnancy, with weekly contacts during the first 6 months and monthly contacts for the next 18 months. Unlimited access to a study website providing self-management tools.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care control condition
Number of subjects: 0
Study: 24259553

Group type: EXPERIMENTAL
Intervention: 2 g eicosapentaenoic acid (EPA) + 1 g docosahexaenoic acid
Number of subjects: 83

Group type: COMPARATOR
Intervention: Corn/soybean oil placebo
Number of subjects: 83
Study: 23752109

Group type: EXPERIMENTAL
Intervention: Trastuzumab for 1 year
Number of subjects: 3401

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 3401
Study: 19404694

Group type: EXPERIMENTAL
Intervention: Alcohol-free chlorhexidine (CHX)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Essential oils (EO)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Water (negative control)
Number of subjects: 20
Study: 18492953

Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 668

Group type: COMPARATOR
Intervention: Control
Number of subjects: 668
Study: 15705012

Group type: EXPERIMENTAL
Intervention: Yi-Gan San (YGS) for 4 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (drug-free) for 4 weeks
Number of subjects: 52
Study: 12742483

Group type: COMPARATOR
Intervention: Tacrolimus (target level 12 to 15 ng/mL in the first month)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Sirolimus (target level 12 to 18 ng/mL in the first month)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 85
Study: 10463905

Group type: EXPERIMENTAL
Intervention: Patulin for the common cold (controlled, double blind mass trial)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Streptomycin (first trial, not double blind or placebo controlled)
Number of subjects: 0
Study: 8671965

Group type: EXPERIMENTAL
Intervention: ANP infusion (0.005 microg/kg*min; group II, n=15)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (group III, n=16)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Healthy subjects (group I, n=10)
Number of subjects: 31
Study: 1834065

Group type: EXPERIMENTAL
Intervention: Nicorandil 4 mg i.v.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Glyceryl trinitrate (GTN) 0.3 mg i.v.
Number of subjects: 20
Study: 7134845

Group type: EXPERIMENTAL
Intervention: 3:1 jejunoileal bypass
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 1:3 jejunoileal bypass
Number of subjects: 34

Group type: COMPARATOR
Intervention: Unoperated group
Number of subjects: 34
Study: 30227147

Group type: EXPERIMENTAL
Intervention: High expectation priming
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Low expectation priming
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Active stimulation with low expectation priming
Number of subjects: 88

Group type: COMPARATOR
Intervention: Sham-controlled anodal tDCS
Number of subjects: 88
Study: 26482574

Group type: EXPERIMENTAL
Intervention: Person-centered physical therapy
Number of subjects: 70
Study: 25133491

Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (TXA) 5% and phenylephrine 0.5%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group with phenylephrine 0.5%
Number of subjects: 60
Study: 22233253

Group type: EXPERIMENTAL
Intervention: Monocyte-derived dendritic cells pulsed with inactivated HIV-1 autologous virus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20346030

Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave lithotripsy (ESWL)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Ureteroscopy (URS)
Number of subjects: 273
Study: 18177775

Group type: EXPERIMENTAL
Intervention: Parenteral ampicillin (100 mg/kg per day in four doses for 48 hours, followed by 3 days of oral amoxicillin (80-90 mg/kg per day); n=1012
Number of subjects: 2037

Group type: COMPARATOR
Intervention: Home-based treatment with oral amoxicillin (80-90 mg/kg per day in two doses for 5 days; n=1025
Number of subjects: 2037

Group type: COMPARATOR
Intervention: Ambulatory group
Number of subjects: 2037

Group type: EXPERIMENTAL
Intervention: Hospitalised group
Number of subjects: 2037
Study: 15797885

Group type: EXPERIMENTAL
Intervention: Naltrexone plus psychotherapy treatment
Number of subjects: 336

Group type: COMPARATOR
Intervention: Psychotherapy treatment alone
Number of subjects: 336
Study: 12748428

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11026862

Group type: EXPERIMENTAL
Intervention: Bladder volume of 100 ml
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bladder volume of 70 ml
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bladder volume of 35 ml
Number of subjects: 30

Group type: COMPARATOR
Intervention: Empty bladder
Number of subjects: 30
Study: 8989778

Group type: EXPERIMENTAL
Intervention: Automated cytology rescreening of Pap smears
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-resolution imaging techniques and computer classifiers
Number of subjects: 0
Study: 1618997

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (120 mg oral)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 4038550

Group type: EXPERIMENTAL
Intervention: Intravenous droperidol
Number of subjects: 23

Group type: COMPARATOR
Intervention: Combination of promethazine and chlorpromazine rectal suppositories
Number of subjects: 23
Study: 31699728

Group type: EXPERIMENTAL
Intervention: Writing Aid software integrating research reporting guidelines
Number of subjects: 54
Study: 28082368

Group type: EXPERIMENTAL
Intervention: Combination of conservative therapies including education for joint protection and OA, a splint for the base of the thumb, hand exercises, and topical diclofenac sodium 1% gel over 6 weeks.
Number of subjects: 204

Group type: COMPARATOR
Intervention: Education for joint protection and OA alone (Control group).
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Combination of conservative therapies (Intervention group).
Number of subjects: 204
Study: 27096878

Group type: EXPERIMENTAL
Intervention: Increased physical activity (200 minutes per week) for 7 years in girls
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Increased physical activity (200 minutes per week) for 7 years in boys
Number of subjects: 364

Group type: COMPARATOR
Intervention: Control group (60 minutes per week) for 7 years in boys
Number of subjects: 364
Study: 24937669

Group type: EXPERIMENTAL
Intervention: DEB-TACE
Number of subjects: 177

Group type: COMPARATOR
Intervention: cTACE
Number of subjects: 177
Study: 22190136

Group type: EXPERIMENTAL
Intervention: 8‐week formula weight‐loss diet 415‐810 kcal per day, followed by 8 weeks on a hypo‐energetic 1200 kcal per day diet
Number of subjects: 192
Study: 20567133

Group type: EXPERIMENTAL
Intervention: Indacaterol 150 microg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Indacaterol 300 microg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Indacaterol 600 microg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50